Immunology MCQ #1

MCQ Source: OSMOSIS

(Answer below)

Which of the following therapeutic antibodies targets CD3 to prevent acute transplant rejection?

A. Rituximab
B. Infliximab
C. Omalizumbab
D. Trastuzamab (Herceptin)
E. Daclizumab
F. Muromonab (OKT3)

(Don’t look down! Choose an answer first…)

_________________________________________________________________________

A. Rituximab
Rituximab targets CD20 to treat B-cell non-Hodgkin’s lymphoma.

B. Infliximab
Infliximab targets TNF-a and is used for Crohns’s disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Etanercept and adalimumab also target TNF-a.

C. Omalizumbab
Omalizumbab targets IgE and is used as an additional (though expensive) line of treatment for severe asthma.

D. Trastuzamab (Herceptin)
Herceptin targets erb-B2 to treat HER-2-overexpressing breast cancer.

E. Daclizumab
Daclizumab targets the IL-2 receptor on activated T cells to prevent acute rejection of renal transplants.

F. Muromonab (OKT3)
Muromonab-CD3 (OKT3) binds to CD3 on the surface of T cells to prevent acute transplant rejection.

Answer is F.

Muromonab-CD3 (OKT3) binds to CD3 on the surface of T cells to prevent acute transplant rejection. The ending “-mab” indicates monoclonal antibody.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s